Postmenopausal Women with Hypoactive Sexual Desire Disorder: Efficacy of Bremelanotide in a Subgroup Analysis
Kingsberg SA, Segraves RT, Clayton AH, et al.
Menopause, 2020 · n = 112
Key finding
Bremelanotide showed 24% response rate in postmenopausal women vs 30% in premenopausal; lower estrogen did not eliminate efficacy.
Summary
Exploratory analysis of Phase 3 trial data examining bremelanotide efficacy specifically in postmenopausal women with acquired HSDD.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT